High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis
- 20 January 2009
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 10 (2), 291-309
- https://doi.org/10.1517/14656560802677882
Abstract
There is at present no cure for multiple sclerosis (MS), and existing therapies are designed primarily to prevent lesion formation, decrease the rate and severity of relapses and delay the resulting disability by reducing levels of inflammation. The aim of this review was to assess the treatment of relapsing MS with particular focus on subcutaneous (s.c.) interferon (IFN) beta-1a. The literature on IFN beta-1a therapy of MS was reviewed based on a PubMed search (English-language publications from 1990) including its pharmacodynamics and pharmacokinetics, clinical efficacy in relapsing MS as shown in placebo-controlled studies and in comparative trials, efficacy in secondary progressive MS, safety and tolerability, and the impact of neutralizing antibodies. The literature suggests that high-dose, high-frequency s.c. IFN beta-1a offers an effective option for treating patients with relapsing MS, with proven long-term safety and tolerability, and has a favourable benefit-to-risk ratio compared with other forms of IFN beta.Keywords
This publication has 100 references indexed in Scilit:
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialThe Lancet Neurology, 2008
- Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosisThe Lancet Neurology, 2005
- New directions in MS therapeutics: vehicles of hopeTrends in Immunology, 2004
- Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosisJournal of Neuroimmunology, 2004
- IFN-β1a and IFN-β1b have different patterns of influence on cytokinesClinical Neurology and Neurosurgery, 2004
- Treatment optimization in multiple sclerosis: report of an international consensus meetingEuropean Journal of Neurology, 2003
- Regulation by interferon β-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patientsNeurochemistry International, 2003
- Interferon‐β treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltrationJournal of Neuroscience Research, 2001
- Efficient Constitutive Production of Human Fibroblast Interferon by Hamster Cells Transformed with the IFN-β1Gene Fused to An SV40 Early PromoterDNA, 1984
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983